Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

Title
Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 101, Issue 2, Pages 219-224
Publisher
Springer Nature
Online
2009-07-01
DOI
10.1038/sj.bjc.6605162

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation